Jiali Wang1,2, Yixuan Zhang1,2, Xiaoquan Liu1,2, Haochen Liu1,2. 1. School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, People's Republic of China. 2. Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, People's Republic of China.
Abstract
OBJECTIVE: The treatment plans designed with the guidance of the mathematical model and adaptive strategy can trap tumor subpopulations in a periodic and controllable loop. But this process requires detailed information about the tumor system, which is difficult to obtain. Therefore, we wondered whether the fixed periodic treatment plans designed with the typical values of population parameters could be applied to a similar tumor system without complete information. METHODS: A binary tumor system constructed by an EGFR-mutant and a KRAS-mutant cell line was used to explore the applicability of the fixed periodic treatment plans. The dynamics of this system were described by combining the Lotka-Volterra model with the framework of the nonlinear mixed-effects model. The typical values of population parameters were used to design the plans, and the robust plans were screened through parameter variation. These screened plans were examined their applicability in animal experiments and simulations. RESULTS: In animal experiments where system parameters vary from -30% to 30%, the "osimertinib administration, withdrawal, FK866 administration and withdrawal" plan can trap subpopulations of the system in periodic cycles. In simulation, when there was an unknown resistant subpopulation, the screened fixed periodic treatment plans can still delay the evolution of resistance. The median outcomes of screened plans were better than conventional sequential treatment in most cases. There was no significant difference between the outcomes of the screened plan with median stability and the optimal therapy. The evolutionary trajectories of these two plans were similar. CONCLUSION: According to the results, these fixed periodic plans should be tried in treatment even the information of the tumor system was incomplete.
OBJECTIVE: The treatment plans designed with the guidance of the mathematical model and adaptive strategy can trap tumor subpopulations in a periodic and controllable loop. But this process requires detailed information about the tumor system, which is difficult to obtain. Therefore, we wondered whether the fixed periodic treatment plans designed with the typical values of population parameters could be applied to a similar tumor system without complete information. METHODS: A binary tumor system constructed by an EGFR-mutant and a KRAS-mutant cell line was used to explore the applicability of the fixed periodic treatment plans. The dynamics of this system were described by combining the Lotka-Volterra model with the framework of the nonlinear mixed-effects model. The typical values of population parameters were used to design the plans, and the robust plans were screened through parameter variation. These screened plans were examined their applicability in animal experiments and simulations. RESULTS: In animal experiments where system parameters vary from -30% to 30%, the "osimertinib administration, withdrawal, FK866 administration and withdrawal" plan can trap subpopulations of the system in periodic cycles. In simulation, when there was an unknown resistant subpopulation, the screened fixed periodic treatment plans can still delay the evolution of resistance. The median outcomes of screened plans were better than conventional sequential treatment in most cases. There was no significant difference between the outcomes of the screened plan with median stability and the optimal therapy. The evolutionary trajectories of these two plans were similar. CONCLUSION: According to the results, these fixed periodic plans should be tried in treatment even the information of the tumor system was incomplete.
Authors: T S Deisboeck; M E Berens; A R Kansal; S Torquato; A O Stemmer-Rachamimov; E A Chiocca Journal: Cell Prolif Date: 2001-04 Impact factor: 6.831
Authors: Daisuke Sano; Tong-Xin Xie; Thomas J Ow; Mei Zhao; Curtis R Pickering; Ge Zhou; Vlad C Sandulache; David A Wheeler; Richard A Gibbs; Carlos Caulin; Jeffrey N Myers Journal: Clin Cancer Res Date: 2011-09-08 Impact factor: 12.531
Authors: Peter J Campbell; Erin D Pleasance; Philip J Stephens; Ed Dicks; Richard Rance; Ian Goodhead; George A Follows; Anthony R Green; P Andy Futreal; Michael R Stratton Journal: Proc Natl Acad Sci U S A Date: 2008-08-22 Impact factor: 11.205
Authors: Jaeyeon Choi; Wissam Beaino; Ronald J Fecek; Kellsye P L Fabian; Charles M Laymon; Brenda F Kurland; Walter J Storkus; Carolyn J Anderson Journal: J Nucl Med Date: 2018-06-29 Impact factor: 10.057